Adenine nucleotides and adenosine are important regulators of dopaminergic transmission in striatum.
Purinergic signalling in striatum is mediated by P1 (adenosine) and P2 (purine nucleotide) receptors.
Adenosine A2A receptor antagonists, such as istradefylline, have potential in the therapy of Parkinson's disease.
Istradefylline is a first in class molecule approved in Japan for use in parkinsonian patients.